
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc is positioned favorably in the biopharmaceutical sector, focusing on innovative treatments for neurodegenerative diseases and psychiatric disorders, particularly Alzheimer's. The company reported positive top-line results in June 2023, indicating promising progress in its clinical development pipeline, which includes unique therapeutic candidates, AL001 and AL002. Additionally, the current valuation of Alzamend Neuro appears attractive, suggesting potential for significant upside as the company continues to achieve key milestones and generates positive data.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly surpassed earlier estimates of $(0.69). The company, operating in the early clinical stages of biopharmaceutical development, is heavily reliant on the success of its two drug candidates aimed at treating neurodegenerative diseases, notably Alzheimer's, which poses inherent risks linked to clinical trial outcomes and regulatory approvals. Additionally, the financial outlook is compounded by balance sheet and liquidity risks, competition, and broader macroeconomic factors, raising concerns about the company's ability to achieve commercialization and secure appropriate reimbursement for its products.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares